These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 34580004)

  • 1. Immune imprinting and SARS-CoV-2 vaccine design.
    Wheatley AK; Fox A; Tan HX; Juno JA; Davenport MP; Subbarao K; Kent SJ
    Trends Immunol; 2021 Nov; 42(11):956-959. PubMed ID: 34580004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection].
    AIDS and Hepatitis C Professional Group, Chinese Society of Infectious Diseases
    Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):615-618. PubMed ID: 34619837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021.
    Glatman-Freedman A; Hershkovitz Y; Kaufman Z; Dichtiar R; Keinan-Boker L; Bromberg M
    Emerg Infect Dis; 2021 Nov; 27(11):2919-2922. PubMed ID: 34570694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination.
    Salzman MB; Huang CW; O'Brien CM; Castillo RD
    Emerg Infect Dis; 2021 Jul; 27(7):1944-1948. PubMed ID: 34034858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
    Sharma D
    Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Vaccine Race: Analysis of Age-Dependent Immune Responses against SARS-CoV-2 Indicates that more than Just One Strategy May Be Needed.
    Jimenez M; Campillo NE; Canelles M
    Curr Med Chem; 2021; 28(20):3964-3979. PubMed ID: 33109026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    Canaday DH; Gravenstein S
    Clin Infect Dis; 2021 Feb; 72(3):513-514. PubMed ID: 33527123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies.
    Payandeh Z; Mohammadkhani N; Nabi Afjadi M; Khalili S; Rajabibazl M; Houjaghani Z; Dadkhah M
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):899-910. PubMed ID: 33307883
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Landscape and progress of global COVID-19 vaccine development.
    Huang HY; Wang SH; Tang Y; Sheng W; Zuo CJ; Wu DW; Fang H; Du Q; Li N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3276-3280. PubMed ID: 34254894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.